I-Abciximab

I-Abciximab umuthi wokulwa nama-platelet ofakwa ngemithambo osetshenziselwa ukuvimbela ukuqhekeka kwegazi ezigulini ezithola izinqubo ezithile zenhliziyo ezinobungozi obukhulu, ikakhulukazi ukungenelela kwe-coronary percutaneous (PCI). Njenge-glycoprotein IIb/IIIa receptor inhibitor, ivimbela ama-platelet ukuthi ahlangane, ngaleyo ndlela inciphise ingozi yokuhlaselwa yinhliziyo, isifo sohlangothi, noma ukuvaleka kwemithambo yegazi ngesikhathi nangemva nje kwalezi zinqubo. Lo mhlahlandlela uhlanganisa konke okudingeka ukwazi nge-Abciximab, okuhlanganisa ukusetshenziswa kwayo, umthamo, imiphumela emibi, ukusebenzisana, kanye nezinzuzo.

Iyini i-Abciximab?

I-Abciximab iyisiqeshana se-antibody se-monoclonal (Fab) esibopha kwi-glycoprotein IIb/IIIa receptor kuma-platelet, okuyindlela yokugcina evamile yokuhlanganiswa kwama-platelet. Ngokuvimba le receptor, i-Abciximab isiza ukunciphisa ingozi yokwakheka kwama-blood clots, ikakhulukazi ezinqubweni zenhliziyo ezinobungozi obukhulu. Ivame ukusetshenziswa ngesikhathi se-angioplasty kanye nezinqubo ezihlobene nayo.

Ukusetshenziswa kwe-Abciximab

I-Abciximab isetshenziswa ngokuyinhloko ukuvimbela ukwakheka kwamahlule ezimweni ezithile zenhliziyo nemithambo yegazi. Ukusetshenziswa okuyinhloko kufaka phakathi:

• Ngesikhathi Sokungenelela Kwenhliziyo Ehamba Ngonyawo (i-PCI): I-Abciximab ivame ukunikezwa iziguli ezenza i-PCI, inqubo yokuvula imithambo yenhliziyo evalekile noma enciphile, ukunciphisa ingozi yokwakheka kwamahlule.
• Ku-Acute Coronary Syndrome (ACS): Ezimweni ze-ACS, lapho ukugeleza kwegazi enhliziyweni kuncipha noma kuvimbeke ngokuzumayo, i-Abciximab inganciphisa ingozi yokuhlaselwa yinhliziyo.
• Ukungenelela kwenhliziyo okuyingozi kakhulu: Ezigulini ezisengozini enkulu yokuvalwa kwemithambo yegazi ngokuzumayo noma i-thrombosis.
• I-Angina Engazinzile noma i-Non-ST Elevation Myocardial Infarction (NSTEMI): Ezigulini ezihlelelwe i-PCI zingakapheli amahora angama-24, ukuze kuncishiswe ingozi yezehlakalo ze-ischemic zenhliziyo.
• Ukuphathwa Kwangemva Kwe-PCI: I-Abciximab ngezinye izikhathi isetshenziswa njengesinyathelo sokuvimbela sesikhashana ukuqinisekisa ukuthi azikho izinkinga ezisheshayo ngemva kwe-PCI noma izinqubo ezifanayo.

Isilinganiso se-Abciximab

Umthamo we-Abciximab uyahlukahluka ngokuya ngenqubo kanye nezici zesiguli. Iziqondiso ezijwayelekile zomthamo zimi kanje:

• Umthamo Wokuqala We-Bolus: Umjovo owodwa we-bolus ongu-0.25 mg/kg ufakwa ngemithambo cishe imizuzu eyi-10 kuya kwengama-60 ngaphambi kwe-PCI.
• Umthamo Wokumnika: Ngemva kokusebenzisa i-bolus yokuqala, kunikezwa i-infusion eqhubekayo engu-0.125 ?g/kg/min amahora ayi-12.

Le nqubo yokulinganisa ivame ukusetshenziswa kubantu abadala abathola i-PCI; noma kunjalo, isilinganiso somuntu ngamunye singahluka. Ukulungiswa kungadingeka ngokusekelwe esisindweni sesiguli, ukusebenza kwezinso, kanye nengozi yokopha. Kubalulekile ukulandela imiyalelo yomhlinzeki wezempilo eduze lapho usebenzisa i-Abciximab.

Indlela I-Abciximab Esebenza Ngayo

I-Abciximab isebenza ngokuvimbela i-platelet glycoprotein IIb/IIIa receptor, isinyathelo sokugcina sokuhlanganiswa kwama-platelet. Lokhu kuvimbela i-fibrinogen namanye ama-molecule anamathelayo ukuthi angabi yingxenye yama-platelet, ngaleyo ndlela kunciphisa ukwakheka kwe-thrombus ngesikhathi sokungenelela kwe-coronary.

Imiphumela Engemihle ye-Abciximab

Njengayo yonke imithi, i-Abciximab inemiphumela emibi engaba khona. Imiphumela emibi evame kakhulu ihlanganisa:

Imiphumela Emibi Evamile:

• Ukopha (ikakhulukazi endaweni yokubhoboza kwemithambo yegazi)
• Ukudabuka noma ukuhlanza
• I-Hypotension
• Ukuhlungu obusemhlane

Imiphumela Emibi Kakhulu:

• Ukopha okukhulu: Ikakhulukazi ukopha kwamathumbu, kwangaphakathi kobuchopho, noma kwangemuva kwesisu.
• I-Thrombocytopenia: Ukwehla okukhulu kwenani lama-platelet kungenzeka, ngezikhathi ezithile kungakapheli amahora amaningi ngemuva kokuphathwa.
• Ukusabela kwe-allergic noma i-anaphylactic: Akuvamile kodwa kungenzeka, ikakhulukazi uma uvame ukuchayeka.

Kubalulekile ukubika noma yimiphi imiphumela emibi kumhlinzeki wakho wezempilo, ikakhulukazi uma imbi kakhulu noma iqhubeka njalo.

Qaphela: I-Abciximab akufanele inikezwe iziguli ezinesifo sokopha okusebenzayo, ukuhlinzwa kwakamuva, noma umlando we-thrombocytopenia ohlotshaniswa nama-glycoprotein IIb/IIIa inhibitors.

Ukusebenzisana Neminye Imithi

I-Abciximab ingasebenzisana neminye imithi, okungase kwandise ingozi yemiphumela emibi noma kunciphise ukusebenza kahle kwayo. Ukusebenzisana okubalulekile kufaka phakathi:

• Ama-Anticoagulant kanye Neminye Imithi Yama-Antiplatelet: Uma kuhlanganiswa nemithi efana ne-heparin, i-aspirin, noma i-clopidogrel, ingozi yokopha iyanda kakhulu. Kudingeka ukuqapha ngokucophelela.
• Izidakamizwa ezingezona ze-steroidal ezilwa nokuvuvukala (ama-NSAID): Ama-NSAID afana ne-ibuprofen angandisa kakhulu ingozi yokopha uma esetshenziswa kanye ne-Abciximab.
• Ama-Thrombolytic Ejenti: Imithi eqeda amahlule egazi ingasebenzisana ne-Abciximab, okuholela ezingozini zokopha ngokweqile.
• Ama-ACE Inhibitors kanye nama-Beta-Blockers: Nakuba kungaxhumani ngqo ne-Abciximab, ukuhlanganisa lokhu ne-Abciximab kungandisa ingozi yokwehla komfutho wegazi.

Njalo yazisa umhlinzeki wakho wezempilo nganoma yimiphi eminye imithi oyithathayo ngaphambi kokuqala i-Abciximab.

Izinzuzo ze-Abciximab

Izifundo zezokwelapha zibonise ukuthi i-Abciximab inciphisa kakhulu ingozi yezinkinga ze-ischemic, i-myocardial infarction, kanye nesidingo sokuvuselelwa kwemithambo yegazi ngokushesha ezigulini ezithola i-PCI. Uma isetshenziswa ne-aspirin ne-heparin, ithuthukisa imiphumela yenqubo futhi ithuthukisa ukuqina kwemithambo yegazi yenhliziyo.

Izinzuzo ze-Abciximab, ikakhulukazi ezigulini ezisengozini enkulu yenhliziyo, zifaka:

• Kunciphisa Ingozi Yokuhlaselwa Yinhliziyo Ngesikhathi Se-PCI: Ukusetshenziswa okuyinhloko kwe-Abciximab ukunciphisa ingozi yokuhlaselwa yinhliziyo ngesikhathi nangemva kwe-PCI.
• Yehlisa Ingozi Yokushaywa Yisifo Sohlangothi: Ngokuvimbela ukwakheka kwamahlule, kunganciphisa ingozi yokushaywa yisifo sohlangothi kwezinye izinqubo zenhliziyo nemithambo yegazi.
• Kuthuthukisa Izinga Lempumelelo ye-PCI: Ngokunciphisa ukwakheka kwamahlule, i-Abciximab isiza ekuthuthukiseni izinga lempumelelo ye-PCI.
• Isivikelo Sesikhathi Esifushane Ngemva kwe-PCI: I-Abciximab inikeza isivikelo sesikhashana esikhathini esiseduze ngemva kwe-PCI, esibalulekile ezigulini ezisengozini enkulu.
• Kubekezelelwa Kahle Ezindaweni Zesibhedlela: Uma inikezwa ngaphansi kokuqashwa okuseduze, i-Abciximab inephrofayili enhle yokuphepha kweziguli ezisengozini enkulu.

imibuzo ejwayelekile ukubuzwa

Umbuzo 1: Isetshenziswa kanjani i-Abciximab?

A: I-Abciximab inikezwa ngemithambo yegazi, ngokuvamile ngomjovo we-bolus olandelwa ukumiliswa okuqhubekayo ngesikhathi sezinqubo ze-PCI.

Umbuzo 2: Ingabe i-Abciximab ingasetshenziswa kuzo zonke izinqubo zenhliziyo nemithambo yegazi?

A: Cha, i-Abciximab iboniswa kuphela ezimweni ezithile zokungenelela kwenhliziyo kanye nezimo ezithile ze-ACS. Ayinconywa ekwelashweni okuvamile kwesikhathi eside kwe-antiplatelet.

Umbuzo 3: I-Abciximab isebenza isikhathi esingakanani?

A: I-Abciximab iqala ukusebenza kungakapheli imizuzu embalwa isetshenzisiwe, okwenza iphumelele kakhulu ekuvimbeleni amahlule ngokushesha ngesikhathi sezinqubo.

UMBUZO 4: Kufanele ngenzeni uma ngiba nemiphumela emibi?

A: Xhumana nomhlinzeki wakho wezempilo ngokushesha uma uhlangabezana nemiphumela emibi ebalulekile, ikakhulukazi ukopha noma izimpawu zokusabela kokungezwani komzimba.

Umbuzo 5: Ngingayithatha yini i-Abciximab kanye neminye imithi yokwehlisa igazi?

A: Ukuhlanganisa i-Abciximab nezinye izidakamizwa zokunciphisa igazi kwandisa ingozi yokopha, ngakho-ke kubalulekile ukulandela isiqondiso somhlinzeki wakho wezempilo.

Umbuzo 6: Umphumela we-Abciximab uhlala isikhathi esingakanani?

A: Imiphumela ye-Abciximab ivame ukuhlala cishe emahoreni angu-48 ngemva kokuphela kokumuncwa, yize umsebenzi wama-platelet ungase uqale ukubuya ngokushesha. Umsebenzi wama-platelet uvame ukubuyela esimweni esijwayelekile zingakapheli amahora angu-24-48 ngemva kokuyeka ukumuncwa.

Umbuzo 7: Ubani okungafanele athathe i-Abciximab?

A: Abantu abanesifo sokopha okusebenzayo, ukuhlinzwa kwakamuva, noma umfutho wegazi ophakeme kakhulu ngokuvamile abafanelekeli i-Abciximab. Njalo xhumana nomhlinzeki wezempilo ukuze uthole izithiyo ezithile. Kuvinjelwe ezigulini ezinesifo sokopha okusebenzayo kwangaphakathi, ukuhlinzwa okukhulu kwakamuva noma ukulimala, umlando wesifo sohlangothi zingakapheli iminyaka emi-2, umfutho wegazi ophakeme ongalawuleki, noma i-thrombocytopenia enzima.

Umbuzo 8: Ingabe kukhona imikhawulo yokudla ngesikhathi usebenzisa i-Abciximab?

A: Nakuba kungekho mingcele ethile yokudla, ukugwema utshwala nama-NSAID kungasiza ekunciphiseni ingozi yokopha. Xhumana nomhlinzeki wakho wezempilo ukuze uthole iseluleko esiqondene nawe.

Umbuzo 9: Ingabe i-Abciximab ingasetshenziswa isikhathi eside?

A: I-Abciximab ivame ukusetshenziswa isikhathi esifushane, ikakhulukazi ngesikhathi se-PCI kanye nezinqubo ezihlobene nayo. Ukusetshenziswa kwesikhathi eside akuvamile.

Umbuzo 10: Yiziphi izinhlobo ze-Abciximab?

A: I-Abciximab ikhangiswa ngaphansi kwegama lomkhiqizo i-ReoPro?. Azikho izinhlobo ezijwayelekile ezitholakalayo njengamanje.

Isiphetho

I-Abciximab iyi-inhibitor ye-glycoprotein IIb/IIIa efakwa ngemithambo esetshenziswa njengesithasiselo ngesikhathi se-PCI ukuvimbela ukuhlangana kwama-platelet nokunciphisa izinkinga ze-ischemic. Uma inikezwa ngaphansi kokuqondisa kochwepheshe, inikeza isivikelo sesikhashana ezigamekweni ze-thrombotic ezigulini ezisengozini enkulu. Kodwa-ke, ngenxa yemiphumela yayo enamandla yokulwa nama-platelet, inengozi enkulu yokopha futhi kumele isetshenziswe ngokuqapha ngokucophelela.